{"id":"aliskiren-hctz-phase-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (with aliskiren)"},{"rate":null,"effect":"Hypokalemia (with HCTZ)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aliskiren is a direct renin inhibitor that prevents the conversion of angiotensinogen to angiotensin I, thereby suppressing the entire RAAS cascade. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that increases sodium and water excretion while causing mild vasodilation. The combination provides complementary antihypertensive effects targeting different pathways of blood pressure regulation.","oneSentence":"Aliskiren blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin, while HCTZ reduces blood pressure through diuresis and vasodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:23.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01519635","phase":"PHASE4","title":"Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2011-10","conditions":"Hypertension","enrollment":24},{"nctId":"NCT01056731","phase":"PHASE4","title":"A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients.","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-02","conditions":"High Blood Pressure","enrollment":253},{"nctId":"NCT01070030","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-01","conditions":"Stage II Hypertension","enrollment":230},{"nctId":"NCT00787605","phase":"PHASE4","title":"Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension, Diabetes Mellitus","enrollment":860},{"nctId":"NCT00739596","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Hypertension","enrollment":332},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00942994","phase":"PHASE4","title":"Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-06","conditions":"Hypertension","enrollment":412},{"nctId":"NCT00705575","phase":"PHASE3","title":"Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-06","conditions":"Hypertension","enrollment":688},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00760266","phase":"PHASE4","title":"Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":451},{"nctId":"NCT00772577","phase":"PHASE4","title":"Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-08","conditions":"Hypertension","enrollment":386},{"nctId":"NCT00797316","phase":"PHASE4","title":"Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Hypertension","enrollment":532}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Aliskiren+HCTZ - Phase 2","genericName":"Aliskiren+HCTZ - Phase 2","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aliskiren blocks the renin-angiotensin-aldosterone system (RAAS) by inhibiting renin, while HCTZ reduces blood pressure through diuresis and vasodilation. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}